HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 56 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $33,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 535,590 | $2,705,000 | 1.58% |
| Millrace Asset Group, Inc. | 200,000 | $1,010,000 | 0.79% |
| Private Wealth Partners, LLC | 1,000,000 | $5,050,000 | 0.77% |
| PERKINS CAPITAL MANAGEMENT INC | 249,700 | $1,261,000 | 0.76% |
| Timpani Capital Management LLC | 206,119 | $1,041,000 | 0.30% |
| Diametric Capital, LP | 64,329 | $325,000 | 0.28% |
| Granahan Investment Management | 941,170 | $4,753,000 | 0.26% |
| Kalos Management, Inc. | 69,900 | $308,000 | 0.16% |
| SYMMETRY PEAK MANAGEMENT LLC | 85,000 | $429,000 | 0.15% |
| B. Riley Wealth Advisors, Inc. | 250,000 | $1,263,000 | 0.15% |